Legend Biotech (LEGN) Net Equity Issued and Repurchased (2020 - 2023)

Legend Biotech's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $114.9 million for Q3 2023.

• Quarterly Net Equity Issued and Repurchased fell 69.58% year-over-year to $114.9 million in Q3 2023, while the trailing twelve-month figure through Sep 2024 was $870.2 million (down 27.1% YoY) and the FY2022 annual result came in at $377.6 million, up 16.76% from the prior year.
• Net Equity Issued and Repurchased was $114.9 million for Q3 2023 at Legend Biotech, down from $377.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $450.1 million in Q4 2020 and bottomed at $114.9 million in Q3 2023.
• A 4-year average of $328.7 million and a median of $377.6 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased climbed 16.76% — and 2023, when it sank 69.58%.
• Legend Biotech's Net Equity Issued and Repurchased stood at $450.1 million in 2020, then slipped by 28.14% to $323.4 million in 2021, then increased by 16.76% to $377.6 million in 2022, then plunged by 69.58% to $114.9 million in 2023.
• Business Quant data shows LEGN's Net Equity Issued and Repurchased at $114.9 million in Q3 2023, $377.6 million in Q4 2022, and $377.6 million in Q3 2022.